vs
Side-by-side financial comparison of Evercore Inc. (EVR) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Evercore Inc. is the larger business by last-quarter revenue ($1.4B vs $783.7M, roughly 1.8× Insulet Corporation). Evercore Inc. runs the higher net margin — 23.0% vs 13.0%, a 10.1% gap on every dollar of revenue. On growth, Evercore Inc. posted the faster year-over-year revenue change (100.3% vs 31.2%). Over the past eight quarters, Evercore Inc.'s revenue compounded faster (42.2% CAGR vs 33.2%).
Evercore Inc., formerly known as Evercore Partners, is a global independent investment banking advisory firm founded in 1995 by Roger Altman, David Offensend, and Austin Beutner. The firm has advised on over $4.7 trillion of merger, acquisition, and restructuring transactions since its founding.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
EVR vs PODD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $783.7M |
| Net Profit | $322.7M | $101.6M |
| Gross Margin | — | 72.6% |
| Operating Margin | — | 18.7% |
| Net Margin | 23.0% | 13.0% |
| Revenue YoY | 100.3% | 31.2% |
| Net Profit YoY | 106.1% | 0.9% |
| EPS (diluted) | $7.20 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.3B | $783.7M | ||
| Q3 25 | $1.0B | $706.3M | ||
| Q2 25 | $838.0M | $649.1M | ||
| Q1 25 | $699.0M | $569.0M | ||
| Q4 24 | $979.5M | $597.5M | ||
| Q3 24 | $738.4M | $543.9M | ||
| Q2 24 | $693.4M | $488.5M |
| Q1 26 | $322.7M | — | ||
| Q4 25 | $204.0M | $101.6M | ||
| Q3 25 | $144.6M | $87.6M | ||
| Q2 25 | $97.2M | $22.5M | ||
| Q1 25 | $146.2M | $35.4M | ||
| Q4 24 | $140.4M | $100.7M | ||
| Q3 24 | $78.4M | $77.5M | ||
| Q2 24 | $73.8M | $188.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 69.7% | ||
| Q1 25 | — | 71.9% | ||
| Q4 24 | — | 72.1% | ||
| Q3 24 | — | 69.3% | ||
| Q2 24 | — | 67.7% |
| Q1 26 | — | — | ||
| Q4 25 | 24.2% | 18.7% | ||
| Q3 25 | 20.8% | 16.7% | ||
| Q2 25 | 18.0% | 18.7% | ||
| Q1 25 | 16.0% | 15.6% | ||
| Q4 24 | 21.8% | 18.3% | ||
| Q3 24 | 16.7% | 16.2% | ||
| Q2 24 | 15.9% | 11.2% |
| Q1 26 | 23.0% | — | ||
| Q4 25 | 15.7% | 13.0% | ||
| Q3 25 | 13.8% | 12.4% | ||
| Q2 25 | 11.6% | 3.5% | ||
| Q1 25 | 20.9% | 6.2% | ||
| Q4 24 | 14.3% | 16.9% | ||
| Q3 24 | 10.6% | 14.2% | ||
| Q2 24 | 10.6% | 38.6% |
| Q1 26 | $7.20 | — | ||
| Q4 25 | $4.80 | $1.42 | ||
| Q3 25 | $3.41 | $1.24 | ||
| Q2 25 | $2.36 | $0.32 | ||
| Q1 25 | $3.48 | $0.50 | ||
| Q4 24 | $3.32 | $1.38 | ||
| Q3 24 | $1.86 | $1.08 | ||
| Q2 24 | $1.81 | $2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | $930.8M |
| Stockholders' EquityBook value | — | $1.5B |
| Total Assets | — | $3.2B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.0B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $1.8B | — | ||
| Q2 24 | $1.7B | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $930.8M | ||
| Q3 25 | — | $934.9M | ||
| Q2 25 | — | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B |
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $1.5B | ||
| Q3 25 | $1.8B | $1.4B | ||
| Q2 25 | $1.7B | $1.5B | ||
| Q1 25 | $1.5B | $1.3B | ||
| Q4 24 | $1.7B | $1.2B | ||
| Q3 24 | $1.6B | $1.1B | ||
| Q2 24 | $1.5B | $998.4M |
| Q1 26 | — | — | ||
| Q4 25 | $5.4B | $3.2B | ||
| Q3 25 | $4.4B | $3.0B | ||
| Q2 25 | $3.7B | $3.5B | ||
| Q1 25 | $3.3B | $3.5B | ||
| Q4 24 | $4.2B | $3.1B | ||
| Q3 24 | $3.6B | $3.0B | ||
| Q2 24 | $3.3B | $2.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $183.3M |
| Free Cash FlowOCF − Capex | — | $48.2M |
| FCF MarginFCF / Revenue | — | 6.2% |
| Capex IntensityCapex / Revenue | — | 17.2% |
| Cash ConversionOCF / Net Profit | — | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | — | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $807.5M | $183.3M | ||
| Q3 25 | $560.9M | $125.7M | ||
| Q2 25 | $437.7M | $196.5M | ||
| Q1 25 | $-549.7M | $63.8M | ||
| Q4 24 | $686.4M | $147.7M | ||
| Q3 24 | $234.5M | $98.5M | ||
| Q2 24 | $348.5M | $96.5M |
| Q1 26 | — | — | ||
| Q4 25 | $798.6M | $48.2M | ||
| Q3 25 | $541.5M | $100.1M | ||
| Q2 25 | $411.7M | $177.9M | ||
| Q1 25 | $-569.3M | $51.5M | ||
| Q4 24 | $673.1M | $94.1M | ||
| Q3 24 | $226.6M | $71.8M | ||
| Q2 24 | $340.7M | $74.0M |
| Q1 26 | — | — | ||
| Q4 25 | 61.6% | 6.2% | ||
| Q3 25 | 51.8% | 14.2% | ||
| Q2 25 | 49.1% | 27.4% | ||
| Q1 25 | -81.4% | 9.1% | ||
| Q4 24 | 68.7% | 15.7% | ||
| Q3 24 | 30.7% | 13.2% | ||
| Q2 24 | 49.1% | 15.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.7% | 17.2% | ||
| Q3 25 | 1.9% | 3.6% | ||
| Q2 25 | 3.1% | 2.9% | ||
| Q1 25 | 2.8% | 2.2% | ||
| Q4 24 | 1.4% | 9.0% | ||
| Q3 24 | 1.1% | 4.9% | ||
| Q2 24 | 1.1% | 4.6% |
| Q1 26 | — | — | ||
| Q4 25 | 3.96× | 1.80× | ||
| Q3 25 | 3.88× | 1.43× | ||
| Q2 25 | 4.50× | 8.73× | ||
| Q1 25 | -3.76× | 1.80× | ||
| Q4 24 | 4.89× | 1.47× | ||
| Q3 24 | 2.99× | 1.27× | ||
| Q2 24 | 4.72× | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EVR
| Advisory Fees (1) | $1.2B | 89% |
| Commissions and Related Revenue | $62.7M | 4% |
| Underwriting Fees | $55.1M | 4% |
| Asset Management and Administration Fees (2) | $23.7M | 2% |
| Other Revenue, net | $15.4M | 1% |
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
